An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
paper
Cited
Public
Unavailable
- Authors
- Anton, Raymond F; Oroszi, Gabor; O'Malley, Stephanie; Couper, David; Swift, Robert; Pettinati, Helen; Goldman, David
- Year
- 2008
- Journal
- Archives of general psychiatry
- PMID
- 18250251
- DOI
- 10.1001/archpsyc.65.2.135
- PMCID
- PMC2666924
CONTEXT: Naltrexone hydrochloride treatment for alcohol dependence works for some individuals but not for everyone. Asn40Asp, a functional polymorphism of the mu-opioid receptor gene (OPRM1), might predict naltrexone response. OBJECTIVE: To evaluate whether individuals with alcoholism who are heterozygous (Asp40/Asn40) or homozygous (Asp40/Asp40) for the OPRM1 Asp40 allele respond better to naltrexone. DESIGN: Pharmacogenetic analysis conducted between January 1, 2001, and January 31, 2004. SETTING: Eleven academic sites in the COMBINE Study. PARTICIPANTS: Recently abstinent volunteers who met all 3 of the following conditions: (1) DSM-IV criteria for primary alcohol dependence; (2) participation in the COMBINE Study; and (3) availability of DNA. INTERVENTIONS: Alcoholic subjects were treated for 16 weeks with 100 mg of naltrexone hydrochloride (234 Asn40 homozygotes and 67 with at least 1 copy of the Asp40 allele) or placebo (235 Asn40 homozygotes and 68 with at least 1 copy of the Asp40 allele). All participants received medical management (MM) alone or with combined behavioral intervention (CBI). MAIN OUTCOME MEASURES: Time trends in percentage of days abstinent, percentage of heavy drinking days, and rates of good clinical outcome. RESULTS: Alcoholic subjects with an Asp40 allele receiving MM alone (no CBI) had an increased percentage of days abstinent (P = .07) and a decreased percentage of heavy drinking days (P = .04) if treated with naltrexone vs placebo, while those with the Asn40/Asn40 genotype showed no medication differences. If treated with MM alone and naltrexone, 87.1% of Asp40 carriers had a good clinical outcome, compared with only 54.8% of individuals with the Asn40/Asn40 genotype (odds ratio, 5.75; confidence interval, 1.88-17.54), while, if treated with placebo, 48.6% of Asp40 carriers and 54.0% of individuals with the Asn40/Asn40 genotype had a good clinical outcome (interaction between medication and genotype, P = .005). No gene x medication interactions were observed in those treated with both MM and CBI. CONCLUSIONS: These results confirm and extend the observation that the functionally significant OPRM1 Asp40 allele predicts naltrexone treatment response in alcoholic individuals. This relationship might be obscured, however, by other efficacious treatments. OPRM1 genotyping in alcoholic individuals might be useful to assist in selecting treatment options. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00006206.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Nalmefene and naltrexone reduce alcohol intake via selective efficacy in subpopulations distinguished by behavioral and blood-based biomarkers. | Farahbakhsh ZZ et al. | β | 2026 | β |
| Neurobiological Consequences of High-Fat High-Sugar Diets on the Mesocorticolimbic System: a Narrative Review. | Atar A | β | 2026 | β |
| Novel biomarkers for alcohol-associated liver disease and their implications across clinical settings. | Rama K et al. | β | 2026 | β |
| The impact of anti-craving medication on cue reactivity and abstinence in patients undergoing alcohol detoxification: some preliminary evidence from a retrospective event-related potentials study. | Dousset C et al. | β | 2026 | β |
| A review of the existing pharmacogenomic literature of naltrexone for use in alcohol use disorder. | Counts C et al. | β | 2025 | β |
| Explaining increased efficacy of naltrexone in the treatment of alcohol dependent patients with a family history of alcohol use disorder: A systematic review on the role of reward sensitivity and sweet liking. | van Amsterdam J et al. | β | 2025 | β |
| Gene polymorphism Mu opioid receptor & its impact on naltrexone treatment response in alcohol-dependent individuals: A pilot study from north India. | Quraishi R et al. | β | 2025 | β |
| Genetic liability for anxiety and treatment response to the monoamine stabilizer OSU6162 in alcohol dependence: a retrospective secondary analysis. | Hong MG et al. | β | 2025 | β |
| <i>OPRM1 rs1799971</i> Polymorphism Predicts Differential Response to Extended-Release Naltrexone in Alcohol Use Disorder: The Interplay of Genetics and Motivation. | Skryabin V et al. | β | 2025 | β |
| Evidence of subgroup differences in meta-analyses evaluating medications for alcohol use disorder: An umbrella review. | Wallach JD et al. | β | 2024 | β |
| Genetic liability for anxiety associates with treatment response to the monoamine stabilizer OSU6162 in alcohol dependence | Hong M et al. | β | 2024 | β |
| Introduction: Approved treatments for alcohol use disorder by regulatory agencies. | Camarini R et al. | β | 2024 | β |
| Medications for treating alcohol use disorder: A narrative review. | Kranzler HR et al. | β | 2023 | β |
| Multi-ancestry study of the genetics of problematic alcohol use in over 1 million individuals. | Zhou H et al. | β | 2023 | β |
| Naltrexone engages a brain reward network in the presence of reward-predictive distractor stimuli in males. | Spencer CN et al. | β | 2023 | β |
| The life and times of endogenous opioid peptides: Updated understanding of synthesis, spatiotemporal dynamics, and the clinical impact in alcohol use disorder. | Margolis EB et al. | β | 2023 | β |
| Translational models of addiction phenotypes to advance addiction pharmacotherapy. | Ray LA et al. | β | 2023 | β |
| Alcohol use disorder: An analysis of the evidence underpinning clinical practice guidelines. | Tanner D et al. | β | 2022 | β |
| Alcohol Use Disorder: Neurobiology and Therapeutics. | Yang W et al. | β | 2022 | β |
| Clinical moderators of response to nalmefene in a randomized-controlled trial for alcohol dependence: An exploratory analysis. | Hashimoto N et al. | β | 2022 | β |
| Knock-In Mouse Models to Investigate the Functions of Opioid Receptors <i>in vivo</i>. | Degrandmaison J et al. | β | 2022 | β |
| Pharmacogenetics of Addiction Therapy. | Graham DP et al. | β | 2022 | β |
| Viral Suppression Levels in Men Who Have Sex With Men and Transgender Women With Newly Diagnosed HIV and Alcohol Use Disorder in Peru: Results From a Randomized, Double-Blind, Placebo-Controlled Trial Using Oral Naltrexone. | Gonzales P et al. | β | 2022 | β |
| Clinical Neuroscience of Addiction: What Clinical Psychologists Need to Know and Why. | Ray LA et al. | β | 2021 | β |
| Developmental Considerations for the Use of Naltrexone in Children and Adolescents. | Stancil SL et al. | β | 2021 | β |
| FMRI-based prediction of naltrexone response in alcohol use disorder: a replication study. | Bach P et al. | β | 2021 | β |
| Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. | Biernacka JM et al. | β | 2021 | β |
| Genomic and Personalized Medicine Approaches for Substance Use Disorders (SUDs) Looking at Genome-Wide Association Studies. | Cozzoli D et al. | β | 2021 | β |
| The Molecular Basis of Alcohol Use Disorder (AUD). Genetics, Epigenetics, and Nutrition in AUD: An Amazing Triangle. | Siomek-Gorecka A et al. | β | 2021 | β |
| What is known about treatment aimed at indigenous people suffering from alcohol use disorder? | Andersen LAK et al. | β | 2021 | β |
| A Call to Action: A Systematic Review Examining the Failure to Include Females and Members of Minoritized Racial/Ethnic Groups in Clinical Trials of Pharmacological Treatments for Alcohol Use Disorder. | Schick MR et al. | β | 2020 | β |
| Differential sensitivity of human neurons carrying ΞΌ opioid receptor (MOR) N40D variants in response to ethanol. | Scarnati MS et al. | β | 2020 | β |
| Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice. | Litten RZ et al. | β | 2020 | β |
| Incubation of neural alcohol cue reactivity after withdrawal and its blockade by naltrexone. | Bach P et al. | β | 2020 | β |
| On the path towards personalized medicine: Implications of pharmacogenetic studies of alcohol use disorder medications. | Nieto SJ et al. | β | 2020 | β |
| Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. | Anton RF et al. | β | 2020 | β |
| Opioid Use among Individuals with Traumatic Brain Injury: A Perfect Storm? | Adams RS et al. | β | 2020 | β |
| OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial. | Hendershot CS et al. | β | 2020 | β |
| Pharmacotherapies and personalized medicine for alcohol use disorder: a review. | Lohoff FW | β | 2020 | β |
| Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. | Hartwell EE et al. | β | 2020 | β |
| Advances in the science and treatment of alcohol use disorder. | Witkiewitz K et al. | β | 2019 | β |
| Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future. | Cannella N et al. | β | 2019 | β |
| Dysmorphic contribution of neurotransmitter and neuroendocrine system polymorphisms to subtherapeutic mood states. | Gonzalez I et al. | β | 2019 | β |
| Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial. | Roche DJO et al. | β | 2019 | β |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | β | 2019 | β |
| Naltrexone Acutely Enhances Connectivity Between the Ventromedial Prefrontal Cortex and a Left Frontoparietal Network. | Elton A et al. | β | 2019 | β |
| Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers. | Green R et al. | β | 2019 | β |
| Pharmacogenetics of alcohol addiction: current perspectives. | Zastrozhin MS et al. | β | 2019 | β |
| Pharmacogenetics of alcohol use disorder treatments: an update. | Hartwell EE et al. | β | 2019 | β |
| Precision psychiatry-What it means for eating disorders? | Kan C et al. | β | 2019 | β |
| Replication of the pharmacogenetic effect of rs678849 on buprenorphine efficacy in African-Americans with opioidΒ use disorder. | Crist RC et al. | β | 2019 | β |
| Reward, Relief and Habit Drinking: Initial Validation of a Brief Assessment Tool. | Grodin EN et al. | β | 2019 | β |
| State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. | Ray LA et al. | β | 2019 | β |
| The Benefits of Obesity Medicine Certification. | Alexander L | β | 2019 | β |
| The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. | de Laat B et al. | β | 2019 | β |
| Therapeutic Drug Monitoring of Naltrexone and 6Ξ²-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges. | BrΓΌnen S et al. | β | 2019 | β |
| Advancing Pharmacotherapy Development from Preclinical Animal Studies. | Egli M | β | 2018 | β |
| A polymorphism in the OPRM1 3'-untranslated region is associated with methadone efficacy in treating opioid dependence. | Crist RC et al. | β | 2018 | β |
| Increased ethanol drinking in "humanized" mice expressing the mu opioid receptor A118G polymorphism are mediated through sex-specific mechanisms. | Henderson-Redmond AN et al. | β | 2018 | β |
| Investigational drugs for alcohol use disorders: a review of preclinical data. | Ch'Ng SS et al. | β | 2018 | β |
| Involvement of Activated Brain Stress Responsive Systems in Excessive and "Relapse" Alcohol Drinking in Rodent Models: Implications for Therapeutics. | Zhou Y et al. | β | 2018 | β |
| Low dose Naltrexone for induction of remission in inflammatory bowel disease patients. | Lie MRKL et al. | β | 2018 | β |
| Molecular Genetics and New Medication Strategies for Opioid Addiction. | Hurd YL et al. | β | 2018 | β |
| Neural and psychological characteristics of college students with alcoholic parents differ depending on current alcohol use. | Brown-Rice KA et al. | β | 2018 | β |
| Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence. | Anton RF et al. | β | 2018 | β |
| [Pharmacotherapies and psychotherapies for Alcohol Dependence]. | Cottencin O | β | 2018 | β |
| Pharmacotherapy for Alcohol Use Disorder. | Holt SR et al. | β | 2018 | β |
| Role of placebo effects in pain and neuropsychiatric disorders. | Belcher AM et al. | β | 2018 | β |
| The OPRM1 A118G polymorphism: converging evidence against associations with alcohol sensitivity and consumption. | Sloan ME et al. | β | 2018 | β |
| Touch-induced face conditioning is mediated by genetic variation in opioid but not oxytocin receptors. | Fu Y et al. | β | 2018 | β |
| Treatment for Alcohol Use Disorder: Progress in Predicting Treatment Outcome and Validating Nonabstinent End Points. | Creswell KG et al. | β | 2018 | β |
| Differential potassium channel gene regulation in BXD mice reveals novel targets for pharmacogenetic therapies to reduce heavy alcohol drinking. | Rinker JA et al. | β | 2017 | β |
| Efficacy of Naltrexone for the Treatment of Alcohol Dependence in Latino Populations. | LΓ³pez CM et al. | β | 2017 | β |
| Low ΞΌ-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis. | Hermann D et al. | β | 2017 | β |
| Metabolomics biomarkers to predict acamprosate treatment response in alcohol-dependent subjects. | Hinton DJ et al. | β | 2017 | β |
| [Pharmacological prophylactic treatment for relapse of alcohol dependence : Results of current meta-analyses]. | Mutschler J et al. | β | 2017 | β |
| Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. | Schacht JP et al. | β | 2017 | β |
| Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models. | Rinker JA et al. | β | 2017 | β |
| Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. | Goh ET et al. | β | 2017 | β |
| Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity. | Cservenka A et al. | β | 2017 | β |
| Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone. | Zhou Y et al. | β | 2017 | β |
| The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target? | Pomrenze MB et al. | β | 2017 | β |
| The genetic epidemiology of substance use disorder: A review. | Prom-Wormley EC et al. | β | 2017 | β |
| The Prescription Opioid Addiction Treatment Study: What have we learned. | Weiss RD et al. | β | 2017 | β |
| Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders. | Kwako LE et al. | β | 2016 | β |
| A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction. | Bell RL et al. | β | 2016 | β |
| A modified classification tree method for personalized medicine decisions. | Tsai WM et al. | β | 2016 | β |
| Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research. | Bujarski S et al. | β | 2016 | β |
| From genetic studies to precision medicine in alcohol dependence. | Sun Y et al. | β | 2016 | β |
| Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption. | McGuier NS et al. | β | 2016 | β |
| Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease. | Gitto S et al. | β | 2016 | β |
| Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives. | Tek C | β | 2016 | β |
| Opioid Antagonists and the A118G Polymorphism in the ΞΌ-Opioid Receptor Gene: Effects of GSK1521498 and Naltrexone in Healthy Drinkers Stratified by OPRM1 Genotype. | Ziauddeen H et al. | β | 2016 | β |
| Opioid neuroscience for addiction medicine: From animal models to FDA approval for alcohol addiction. | Berrettini W | β | 2016 | β |
| Primary Care Providers' Interest in Using a Genetic Test to Guide Alcohol Use Disorder Treatment. | Williams EC et al. | β | 2016 | β |
| Rearing environment differentially modulates cocaine self-administration after opioid pretreatment: A behavioral economic analysis. | Hofford RS et al. | β | 2016 | β |
| Sweet taste pleasantness is modulated by morphine and naltrexone. | Eikemo M et al. | β | 2016 | β |
| Treatment of alcohol use disorders in patients with alcoholic liver disease. | Addolorato G et al. | β | 2016 | β |
| Treatment-refractory substance use disorder: Focus on alcohol, opioids, and cocaine. | Soyka M et al. | β | 2016 | β |
| What does addiction medicine expect from neuroscience? From genes and neurons to treatment responses. | Le Foll B | β | 2016 | β |
| Addiction pharmacogenetics: a systematic review of the genetic variation of the dopaminergic system. | Patriquin MA et al. | β | 2015 | β |
| Advances in Medications and Tailoring Treatment for Alcohol Use Disorder. | Seneviratne C et al. | β | 2015 | β |
| Alcohol Consumption in Healthy OPRM1 G Allele Carriers and Its Association with Impulsive Behavior. | Pfeifer P et al. | β | 2015 | β |
| An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. | Gueorguieva R et al. | β | 2015 | β |
| A pharmacogenetic determinant of mu-opioid receptor antagonist effects on alcohol reward and consumption: evidence from humanized mice. | Bilbao A et al. | β | 2015 | β |
| Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings. | Fredriksson I et al. | β | 2015 | β |
| From translational neuroscience to personalized medicine. | Krystal JH et al. | β | 2015 | β |
| Gene-gene interaction of ΞΌ-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect. | Misailidis G et al. | β | 2015 | β |
| Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. | Bress A et al. | β | 2015 | β |
| KCNN Genes that Encode Small-Conductance Ca2+-Activated K+ Channels Influence Alcohol and Drug Addiction. | Padula AE et al. | β | 2015 | β |
| Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function. | Mague SD et al. | β | 2015 | β |
| OPRM1 genotype and naltrexone response in depressed alcohol-dependent patients. | Foulds JA et al. | β | 2015 | β |
| Pharmacogenetics of alcohol use disorders and comorbid psychiatric disorders. | Helton SG et al. | β | 2015 | β |
| Pharmacotherapy for alcohol dependence: A stratified approach. | Thompson A et al. | β | 2015 | β |
| Pharmacotherapy for alcohol use disorder: current and emerging therapies. | Swift RM et al. | β | 2015 | β |
| Predicting outcome of substance abuse treatment in a feedback study: Can recovery curves be improved upon? | Crits-Christoph P et al. | β | 2015 | β |
| Sex differences in acute hormonal and subjective response to naltrexone: The impact of menstrual cycle phase. | Roche DJ et al. | β | 2015 | β |
| Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study. | Worley MJ et al. | β | 2015 | β |
| Subjective response as a consideration in the pharmacogenetics of alcoholism treatment. | Roche DJ et al. | β | 2015 | β |
| The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. | Paterson LM et al. | β | 2015 | β |
| The opioid receptors as targets for drug abuse medication. | Noble F et al. | β | 2015 | β |
| The pharmacogenetics of alcohol use disorder. | Jones JD et al. | β | 2015 | β |
| The pharmacology of neurokinin receptors in addiction: prospects for therapy. | Sandweiss AJ et al. | β | 2015 | β |
| The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review. | Bauer IE et al. | β | 2015 | β |
| Addiction science: Uncovering neurobiological complexity. | Volkow ND et al. | β | 2014 | β |
| Alcohol-medical drug interactions. | Johnson BA et al. | β | 2014 | β |
| Clinical and biological moderators of response to naltrexone in alcohol dependence: a systematic review of the evidence. | Garbutt JC et al. | β | 2014 | β |
| Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats. | Henderson-Redmond A et al. | β | 2014 | β |
| Familial risk for alcohol dependence and developmental changes in BMI: the moderating influence of addiction and obesity genes. | Lichenstein SD et al. | β | 2014 | β |
| Future pharmacological treatments for substance use disorders. | Forray A et al. | β | 2014 | β |
| Genetic influences on response to alcohol and response to pharmacotherapies for alcoholism. | Enoch MA | β | 2014 | β |
| Genetic polymorphisms and response to medications for alcohol use disorders: a systematic review and meta-analysis. | Jonas DE et al. | β | 2014 | β |
| Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol. | Ray LA et al. | β | 2014 | β |
| [Nalmefene: a novel pharmacotherapeutic option for alcoholism]. | Soyka M | β | 2014 | β |
| Nalmefene for the treatment of alcohol dependence: a current update. | Soyka M | β | 2014 | β |
| Neurochemical mechanisms of alcohol withdrawal. | Becker HC et al. | β | 2014 | β |
| Neuroimmune basis of methamphetamine toxicity. | Loftis JM et al. | β | 2014 | β |
| Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. | Hendershot CS | β | 2014 | β |
| Pharmacogenetics of addiction therapy. | Nielsen DA et al. | β | 2014 | β |
| Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. | Arias AJ et al. | β | 2014 | β |
| Pharmacogenetics of OPRM1. | Crist RC et al. | β | 2014 | β |
| Pharmacological approaches to reducing craving in patients with alcohol use disorders. | Haass-Koffler CL et al. | β | 2014 | β |
| Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond. | Caputo F et al. | β | 2014 | β |
| Pharmacologic treatment of alcoholism. | Anton RF et al. | β | 2014 | β |
| Pharmacotherapy of alcohol use disorders: seventy-five years of progress. | Zindel LR et al. | β | 2014 | β |
| Predicting naltrexone response in alcohol-dependent patients: the contribution of functional magnetic resonance imaging. | Mann K et al. | β | 2014 | β |
| Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention. | Skala K et al. | β | 2014 | β |
| The behavioral economics of substance use disorders: reinforcement pathologies and their repair. | Bickel WK et al. | β | 2014 | β |
| The Genetics, Neurogenetics and Pharmacogenetics of Addiction. | Demers CH et al. | β | 2014 | β |
| Topiramate for alcoholism treatment: novel pharmacogenetic evidence for the journey to personalized medicine? | Leggio L et al. | β | 2014 | β |
| Toward personalized medicine in the pharmacotherapy of alcohol use disorder: targeting patient genes and patient goals. | Batki SL et al. | β | 2014 | β |
| Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? | Weiss RD et al. | β | 2014 | β |
| A cross-sectional study of attitudes about the use of genetic testing for clinical care among patients with an alcohol use disorder. | Strobel B et al. | β | 2013 | β |
| Activation of PPARΞ³ by pioglitazone potentiates the effects of naltrexone on alcohol drinking and relapse in msP rats. | Stopponi S et al. | β | 2013 | β |
| Alcohol addiction: toward a patient-oriented pharmacological treatment. | Addolorato G et al. | β | 2013 | β |
| A systems medicine research approach for studying alcohol addiction. | Spanagel R et al. | β | 2013 | β |
| DSM-5 criteria for substance use disorders: recommendations and rationale. | Hasin DS et al. | β | 2013 | β |
| Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects. | Ziauddeen H et al. | β | 2013 | β |
| Improving clinical outcomes for naltrexone as a management of problem alcohol use. | Hulse GK | β | 2013 | β |
| Influence of OPRM1 Asn40Asp variant (A118G) on [11C]carfentanil binding potential: preliminary findings in human subjects. | Weerts EM et al. | β | 2013 | β |
| Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. | Schacht JP et al. | β | 2013 | β |
| Management of alcohol dependence in patients with liver disease. | Addolorato G et al. | β | 2013 | β |
| Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone. | Ducat E et al. | β | 2013 | β |
| Naltrexone treatment for opioid dependence: does its effectiveness depend on testing the blockade? | Sullivan MA et al. | β | 2013 | β |
| Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. | Hendrickson LM et al. | β | 2013 | β |
| Novelty-seeking behaviors and the escalation of alcohol drinking after abstinence in mice are controlled by metabotropic glutamate receptor 5 on neurons expressing dopamine d1 receptors. | Parkitna JR et al. | β | 2013 | β |
| Opioid pharmacogenetics of alcohol addiction. | Berrettini W | β | 2013 | β |
| Opioid receptor polymorphism A118G associated with clinical severity in a drug overdose population. | Manini AF et al. | β | 2013 | β |
| Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study. | Dreifuss JA et al. | β | 2013 | β |
| Peter Riederer "70th birthday" neurobiological foundations of modern addiction treatment. | Jacob C | β | 2013 | β |
| Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. | Hajj A et al. | β | 2013 | β |
| Subjective response to alcohol among alcohol-dependent individuals: effects of the ΞΌ-opioid receptor (OPRM1) gene and alcoholism severity. | Ray LA et al. | β | 2013 | β |
| Targeted opioid receptor antagonists in the treatment of alcohol use disorders. | Niciu MJ et al. | β | 2013 | β |
| Variation in Mu-Opioid Receptor Gene <i>(OPRM1)</i> as a Moderator of Naltrexone Treatment to Reduce Heavy Drinking in a High Functioning Cohort. | Chen AC et al. | β | 2013 | β |
| Variation in OPRM1 moderates the effect of desire to drink on subsequent drinking and its attenuation by naltrexone treatment. | Kranzler HR et al. | β | 2013 | β |
| A preliminary examination of how serotonergic polymorphisms influence brain response following an adolescent cannabis intervention. | Feldstein Ewing SW et al. | β | 2012 | β |
| Association of Β΅-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. | Chamorro AJ et al. | β | 2012 | β |
| BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. | Lingford-Hughes AR et al. | β | 2012 | β |
| Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. | Fucito LM et al. | β | 2012 | β |
| [Clinical alcohology]. | Cottencin O et al. | β | 2012 | β |
| Common and specific liability to addiction: approaches to association studies of opioid addiction. | Nielsen DA et al. | β | 2012 | β |
| Current progress in pharmacologic treatment strategies for alcohol dependence. | Clapp P | β | 2012 | β |
| Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol. | Ashenhurst JR et al. | β | 2012 | β |
| Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value. | Mathews R et al. | β | 2012 | β |
| Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists. | van Rijn RM et al. | β | 2012 | β |
| Family history of alcohol dependence and antidepressant response to an N-methyl-D-aspartate antagonist in bipolar depression. | Luckenbaugh DA et al. | β | 2012 | β |
| Genetics and genomics: unraveling new opportunities for addiction treatment and education. | Snow D et al. | β | 2012 | β |
| Hypermethylation of OPRM1 promoter region in European Americans with alcohol dependence. | Zhang H et al. | β | 2012 | β |
| Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone. | Setiawan E et al. | β | 2012 | β |
| Management of alcohol abuse. | Albanese AP | β | 2012 | β |
| Mu opioid receptor (OPRM1) as a predictor of treatment outcome in opiate-dependent individuals of Arab descent. | Al-Eitan LN et al. | β | 2012 | β |
| Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. | Anton RF et al. | β | 2012 | β |
| OPRM1 and diagnosis-related posttraumatic stress disorder in binge-drinking patients living with HIV. | Nugent NR et al. | β | 2012 | β |
| Pharmacogenetically driven treatments for alcoholism: are we there yet? | Arias AJ et al. | β | 2012 | β |
| Pharmacogenetics of alcoholism: a clinical neuroscience perspective. | Ray LA et al. | β | 2012 | β |
| Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study. | Ray LA et al. | β | 2012 | β |
| Possible association between OPRM1 genetic variance at the 118 locus and alcohol dependence in a large treatment sample: relationship to alcohol dependence symptoms. | Koller G et al. | β | 2012 | β |
| The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration. | Srinivasan S et al. | β | 2012 | β |
| The genetic basis of addictive disorders. | Ducci F et al. | β | 2012 | β |
| The genetics of addiction-a translational perspective. | Agrawal A et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. | Ray LA et al. | β | 2012 | β |
| Translational behaviour-genetic studies of alcohol: are we there yet? | Crabbe JC | β | 2012 | β |
| Understanding naltrexone mechanism of action and pharmacogenetics in Asian Americans via behavioral economics: a preliminary study. | Bujarski S et al. | β | 2012 | β |
| A genetic determinant of the striatal dopamine response to alcohol in men. | Ramchandani VA et al. | β | 2011 | β |
| Alcohol research: past, present, and future. | Gunzerath L et al. | β | 2011 | β |
| A preliminary investigation of varenicline for heavy drinking smokers. | Fucito LM et al. | β | 2011 | β |
| Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal. | Ripley TL et al. | β | 2011 | β |
| Gender-specific interactions between alcohol metabolism genes and severity of quantitative alcohol-related-traits in a Tibetan population. | Guo WJ et al. | β | 2011 | β |
| Genetics of alcohol dependence. | Kimura M et al. | β | 2011 | β |
| Implication of the purinergic system in alcohol use disorders. | Asatryan L et al. | β | 2011 | β |
| Implications from addiction research towards the understanding and treatment of obesity. | Grosshans M et al. | β | 2011 | β |
| Medications for unhealthy alcohol use: across the spectrum. | O'Malley SS et al. | β | 2011 | β |
| Naltrexone depot formulations for opioid and alcohol dependence: a systematic review. | Lobmaier PP et al. | β | 2011 | β |
| Opiate-induced dopamine release is modulated by severity of alcohol dependence: an [(18)F]fallypride positron emission tomography study. | Spreckelmeyer KN et al. | β | 2011 | β |
| Opioid modulators for alcohol dependence. | Hillemacher T et al. | β | 2011 | β |
| OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence. | Coller JK et al. | β | 2011 | β |
| OPRM1 gene variation influences hypothalamic-pituitary-adrenal axis function in response to a variety of stressors in rhesus macaques. | Schwandt ML et al. | β | 2011 | β |
| Personalized addiction treatment: how close are we? | Oslin D | β | 2011 | β |
| Pharmacogenetic approaches to the treatment of alcohol addiction. | Heilig M et al. | β | 2011 | β |
| Pharmacogenetics of alcohol, nicotine and drug addiction treatments. | Sturgess JE et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| Relapse prevention for addictive behaviors. | Hendershot CS et al. | β | 2011 | β |
| The effect of naltrexone on alcohol's stimulant properties and self-administration behavior in social drinkers: influence of gender and genotype. | Setiawan E et al. | β | 2011 | β |
| To be or not to be--obese. | Maudsley S et al. | β | 2011 | β |
| Alcohol cue reactivity task development. | Pulido C et al. | β | 2010 | β |
| Alcohol response and consumption in adolescent rhesus macaques: life history and genetic influences. | Schwandt ML et al. | β | 2010 | β |
| A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys. | Vallender EJ et al. | β | 2010 | β |
| Chronic ethanol exposure produces tolerance to elevations in neuroactive steroids: mechanisms and reversal by exogenous ACTH. | Boyd KN et al. | β | 2010 | β |
| Commentary on Nelson et al. (2010). | Barr CS | β | 2010 | β |
| Consilient research approaches in studying gene x environment interactions in alcohol research. | Sher KJ et al. | β | 2010 | β |
| Covariates of craving in actively drinking alcoholics. | Chakravorty S et al. | β | 2010 | β |
| Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. | Zhou Y et al. | β | 2010 | β |
| Emerging drugs to treat alcoholism. | Soyka M et al. | β | 2010 | β |
| Ethanol exposure selectively alters beta-endorphin content but not [3H]-DAMGO binding in discrete regions of the rat brain. | Leriche M et al. | β | 2010 | β |
| Genes and alcohol. | Osby U et al. | β | 2010 | β |
| Individualised treatment in alcohol-dependent patients. | Mann K et al. | β | 2010 | β |
| Initial evidence of an association between OPRM1 and adolescent alcohol misuse. | Miranda R et al. | β | 2010 | β |
| Medication treatment of different types of alcoholism. | Johnson BA | β | 2010 | β |
| Molecular basis and current treatment for alcoholic liver disease. | Miranda-Mendez A et al. | β | 2010 | β |
| Nalmefene for treatment of alcohol dependence. | Soyka M et al. | β | 2010 | β |
| Naltrexone selectively elevates GABAergic neuroactive steroid levels in heavy drinkers with the Asp40 allele of the OPRM1 gene: a pilot investigation. | Ray LA et al. | β | 2010 | β |
| Neural markers of genetic vulnerability to drug addiction. | MΓΌller DJ et al. | β | 2010 | β |
| Opioid antagonists for alcohol dependence. | RΓΆsner S et al. | β | 2010 | β |
| Opioids in the hypothalamic paraventricular nucleus stimulate ethanol intake. | Barson JR et al. | β | 2010 | β |
| Opioids in the hypothalamus control dopamine and acetylcholine levels in the nucleus accumbens. | Rada P et al. | β | 2010 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. | Harris AH et al. | β | 2010 | β |
| Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. | Ray LA et al. | β | 2010 | β |
| Preclinical evidence of new opioid modulators for the treatment of addiction. | RodrΓguez-Arias M et al. | β | 2010 | β |
| Quetiapine for the treatment of alcoholism: scientific rationale and review of the literature. | Ray LA et al. | β | 2010 | β |
| Subjective responses to alcohol consumption as endophenotypes: advancing behavioral genetics in etiological and treatment models of alcoholism. | Ray LA et al. | β | 2010 | β |
| Substance use disorders: realizing the promise of pharmacogenomics and personalized medicine. | Hutchison KE | β | 2010 | β |
| Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. | Barr CS et al. | β | 2010 | β |
| The Effects of Naltrexone Among Alcohol Non-Abstainers: Results from the COMBINE Study. | Ray LA et al. | β | 2010 | β |
| Topiramate in the treatment of substance-related disorders: a critical review of the literature. | Shinn AK et al. | β | 2010 | β |
| Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. | Heilig M et al. | β | 2010 | β |
| Acamprosate and naltrexone treatment effects on ethanol and sucrose seeking and intake in ethanol-dependent and nondependent rats. | Czachowski CL et al. | β | 2009 | β |
| Alcoholism: a systems approach from molecular physiology to addictive behavior. | Spanagel R | β | 2009 | β |
| A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. | Kim SG et al. | β | 2009 | β |
| A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. | Ray LA et al. | β | 2009 | β |
| A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. | Brown ES et al. | β | 2009 | β |
| Association between personality traits and ALDH2 polymorphism in Japanese male alcoholics. | Kimura M et al. | β | 2009 | β |
| Bidirectional translational research: Progress in understanding addictive diseases. | Kreek MJ et al. | β | 2009 | β |
| Daily ratings measures of alcohol craving during an inpatient stay define subtypes of alcohol addiction that predict subsequent risk for resumption of drinking. | Oslin DW et al. | β | 2009 | β |
| Development of pharmacotherapies for drug addiction: a Rosetta stone approach. | Koob GF et al. | β | 2009 | β |
| Do genetic and individual risk factors moderate the efficacy of motivational enhancement therapy? Drinking outcomes with an emerging adult sample. | Feldstein Ewing SW et al. | β | 2009 | β |
| Effects of alcoholism typology on response to naltrexone in the COMBINE study. | Bogenschutz MP et al. | β | 2009 | β |
| Endogenous opiates and behavior: 2008. | Bodnar RJ | β | 2009 | β |
| Ethical considerations for administering alcohol or alcohol cues to treatment-seeking alcoholics in a research setting: can the benefits to society outweigh the risks to the individual? A commentary in the context of the National Advisory Council on Alcohol Abuse and Alcoholism -- Recommended Council Guidelines on Ethyl Alcohol Administration in Human Experimentation (2005). | Enoch MA et al. | β | 2009 | β |
| From the brain to bad behaviour and back again: neurocognitive and psychobiological mechanisms of driving while impaired by alcohol. | Brown TG et al. | β | 2009 | β |
| Genes and addictions. | Bevilacqua L et al. | β | 2009 | β |
| Genetics of alcohol dependence. | Gelernter J et al. | β | 2009 | β |
| Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. | Mague SD et al. | β | 2009 | β |
| Naltrexone for the treatment of alcohol dependence among African Americans: results from the COMBINE Study. | Ray LA et al. | β | 2009 | β |
| Nicotine withdrawal sensitivity, linkage to chr6q26, and association of OPRM1 SNPs in the SMOking in FAMilies (SMOFAM) sample. | Hardin J et al. | β | 2009 | β |
| Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network. | Boettiger CA et al. | β | 2009 | β |
| Opioids in the nucleus accumbens stimulate ethanol intake. | Barson JR et al. | β | 2009 | β |
| OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. | Oroszi G et al. | β | 2009 | β |
| Penn/VA center for studies of addiction. | O'Brien CP et al. | β | 2009 | β |
| Predicting the effect of naltrexone and acamprosate in alcohol-dependent patients using genetic indicators. | Ooteman W et al. | β | 2009 | β |
| Relatively strong automatic appetitive action-tendencies in male carriers of the OPRM1 G-allele. | Wiers RW et al. | β | 2009 | β |
| Role of the HPA axis and the A118G polymorphism of the mu-opioid receptor in stress-induced drinking behavior. | Pratt WM et al. | β | 2009 | β |
| Searching for responders to acamprosate and naltrexone in alcoholism treatment: rationale and design of the PREDICT study. | Mann K et al. | β | 2009 | β |
| Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence. | Garbutt JC et al. | β | 2009 | β |
| The G allele of SNP E1/A118G at the mu-opioid receptor gene locus shows genomic evidence of recent positive selection. | Pang GS et al. | β | 2009 | β |
| The genetics of alcoholism. | Stacey D et al. | β | 2009 | β |
| Typologies of alcohol dependence. From Jellinek to genetics and beyond. | Leggio L et al. | β | 2009 | β |
| Association between single nucleotide polymorphisms in the mu opioid receptor gene (OPRM1) and self-reported responses to alcohol in American Indians. | Ehlers CL et al. | β | 2008 | β |
| Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. | Arias AJ et al. | β | 2008 | β |
| Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence. | Suh JJ et al. | β | 2008 | β |
| Genetic approaches to addiction: genes and alcohol. | Ducci F et al. | β | 2008 | β |
| Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence. | Anton RF | β | 2008 | β |
| Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. | O'Malley SS et al. | β | 2008 | β |
| Response: anticipating new medications. | Bogenschutz MP et al. | β | 2008 | β |
| Review. Evidence-based treatments of addiction. | O'Brien CP | β | 2008 | β |
| Review. Neurogenetic studies of alcohol addiction. | Crabbe JC | β | 2008 | β |
| Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism. | Krishnan-Sarin S et al. | β | 2008 | β |
| Pharmacogenetic aspects of addictive behaviors. | Hejazi NS | β | 2007 | β |